Page 482 - Binder2

(pg. 356) Su, J., Zhu, L., Sherman, A., Wang, X., Lin, S.,
Kamesh, A., & Daniell, H. (2015). Low cost industrial
production of coagulation factor IX bioencapsulated in
lettuce cells for oral tolerance induction in hemophilia B.
Biomaterials, 70, 84–93.
https://doi.org/10.1016/j.biomaterials.2015.08.008

(pg. 240) Arntzen, C. J. (2015). Plant-made
pharmaceuticals: from 'Edible Vaccines' to Ebola
therapeutics. Plant Biotechnology Journal, 13(8), 1013–
1016. https://doi.org/10.1111/pbi.12426

(pg. 151) COUR Pharmaceuticals. (2022). TAK-101 Phase
II Trial Results in Celiac Disease. Presented at Digestive
Disease Week (DDW). Summary available from:
https://www.courpharma.com

(pg. 245) U.S. Department of Health and Human Services.
(2020). Cold Chain Management for Biologics. FDA
Guidelines. https://www.fda.gov

(pg. 360) National Institutes of Health. (n.d.). Autoimmune
Diseases Coordinating Committee Reports.
https://www.niaid.nih.gov/research/autoimmune-diseases

(pg. 240) ClinicalTrials.gov. (2023). Study Record Detail:
Oral Enzyme Therapy in Gaucher’s Disease Using Plant-
Based Expression Systems. [NCT04874312]

(pg. 310) Pharma Intelligence. (2023). Global Biologic
Drug Adherence Report: Oral vs. Injectable Modalities.
Pharma Intelligence Report Series.

480